Evidence map›Paper›PMID 41236470›Full record

ArticleJACC. Case reports2026

Malignant Hypertension-Induced Thrombotic Microangiopathy Mimicking Atypical Hemolytic Uremic Syndrome and Thrombotic Thrombocytopenic Purpura.

Mariana Valdez-Thomas, Michelle Carrasquel-Alvarez, Maria Del Pilar Acosta, Ynsnardy Jose Hurtado-Leon, Mauricio Sosa Quintanilla, Sumesh Khanal

Abstract readCase Reports
In one paragraph

Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mariana Valdez-ThomasMontefiore Medical Center at New Rochelle, Albert Einstein College of Medicine, Bronx, New York, USA. Electronic address: marianavaldez1083@gmail.com.
Michelle Carrasquel-AlvarezMcLaren Greater Lansing, Michigan State University, East Lansing, Michigan, USA.
Maria Del Pilar AcostaMontefiore Medical Center at New Rochelle, Albert Einstein College of Medicine, Bronx, New York, USA.
Ynsnardy Jose Hurtado-LeonMontefiore Medical Center at New Rochelle, Albert Einstein College of Medicine, Bronx, New York, USA.
Mauricio Sosa QuintanillaMontefiore Medical Center at New Rochelle, Albert Einstein College of Medicine, Bronx, New York, USA.
Sumesh KhanalMontefiore Medical Center at New Rochelle, Albert Einstein College of Medicine, Bronx, New York, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMalignant hypertension can present with thrombotic microangiopathy (TMA) that closely resembles thrombotic thrombocytopenic purpura (TTP) and atypical hemolytic uremic syndrome (aHUS). Distinguishing these entities is critical because treatment strategies differ. CASE SUMMARY: We present a 26-year-old man with no prior medical history who developed abdominal pain, blurred vision, and severe hypertension (252/161 mm Hg). Initial management prioritized blood pressure control for malignant hypertension with acute kidney injury. Laboratory testing revealed anemia, thrombocytopenia, hemolysis, and renal dysfunction, raising concern for aHUS/TTP and prompting early nephrology consultation. Further evaluation, including preserved ADAMTS13 activity and the context of hypertensive retinopathy, supported malignant hypertension-induced TMA. With aggressive blood pressure control, renal function and platelet count improved, avoiding unnecessary plasma exchange. DISCUSSION: TMA induced by malignant hypertension mimics TTP and aHUS but typically presents with extreme hypertension, hypertensive retinopathy, relatively higher platelet counts, preserved ADAMTS13 activity, and biopsy- or smear-proven vascular changes. Recognizing these distinctions and consulting nephrology early prevents unnecessary interventions and ensures appropriate therapy.

conclusionsMalignant hypertension is an important cause of secondary TMA. Controlled blood pressure reduction is the cornerstone of therapy. Multidisciplinary collaboration with nephrology helps confirm the diagnosis and guide plasma exchange decisions.

Indexed as

blood testshemostasishypertension

Identifiers

PMID41236470
PMCPMC12833676

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.